XJPX6568
Market cap53mUSD
Jan 17, Last price
1,088.00JPY
1D
-0.27%
1Q
-5.23%
IPO
-67.91%
Name
KNC Laboratories Co Ltd
Chart & Performance
P/E
5.62
P/S
0.92
EPS
193.65
Div Yield, %
3.03%
Shrs. gr., 5y
—
Rev. gr., 5y
6.60%
Revenues
9.15b
+6.10%
Net income
1.49b
-3.23%
CFO
3.20b
+60.71%
Dividend
Mar 28, 202517 JPY/sh
Profile
KNC Laboratories Co., Ltd. engages in the research, development, and production solutions of organic chemicals in Japan. The company offers products for use in the pharmaceutical, electronic-chemical, agrochemical, energy, and environment fields. It offers support services for drugs and functional chemicals. The company was incorporated in 1985 and is headquartered in Kobe, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 9,154,577 6.10% | 8,628,009 15.96% | 7,440,588 23.41% | ||
Cost of revenue | 5,973,817 | 5,461,219 | 5,460,400 | ||
Unusual Expense (Income) | |||||
NOPBT | 3,180,760 | 3,166,790 | 1,980,188 | ||
NOPBT Margin | 34.75% | 36.70% | 26.61% | ||
Operating Taxes | 600,155 | 629,520 | 273,302 | ||
Tax Rate | 18.87% | 19.88% | 13.80% | ||
NOPAT | 2,580,605 | 2,537,270 | 1,706,886 | ||
Net income | 1,493,023 -3.23% | 1,542,843 139.77% | 643,463 61.00% | ||
Dividends | (254,394) | (271,646) | (193,905) | ||
Dividend yield | 2.26% | 2.24% | 2.30% | ||
Proceeds from repurchase of equity | (34) | (111,538) | |||
BB yield | 0.00% | 0.92% | |||
| Debt | |||||
Debt current | 658,347 | 939,980 | 639,980 | ||
Long-term debt | 1,311,719 | 596,730 | 1,036,710 | ||
Deferred revenue | 923,310 | 9,447 | (80,329) | ||
Other long-term liabilities | 330,960 | 4,337 | 293,065 | ||
Net debt | (1,685,771) | (993,303) | (551,162) | ||
| Cash flow | |||||
Cash from operating activities | 3,204,538 | 1,993,942 | 585,109 | ||
CAPEX | (2,354,382) | (1,130,212) | (833,379) | ||
Cash from investing activities | (2,369,133) | (1,146,863) | (613,514) | ||
Cash from financing activities | 178,866 | (523,391) | 39,017 | ||
FCF | 331,912 | 1,839,375 | 1,039,724 | ||
| Balance | |||||
Cash | 3,311,547 | 2,297,276 | 1,973,588 | ||
Long term investments | 344,290 | 232,737 | 254,264 | ||
Excess cash | 3,198,108 | 2,098,613 | 1,855,823 | ||
Stockholders' equity | 7,268,012 | 9,953,206 | 8,704,946 | ||
Invested Capital | 13,113,075 | 10,579,590 | 10,172,133 | ||
ROIC | 21.78% | 24.45% | 17.23% | ||
ROCE | 19.50% | 24.36% | 16.35% | ||
| EV | |||||
Common stock shares outstanding | 7,716 | 7,712 | 7,773 | ||
Price | 1,460.00 -7.36% | 1,576.00 45.52% | 1,083.00 -27.32% | ||
Market cap | 11,265,180 -7.31% | 12,153,921 44.38% | 8,418,207 -27.15% | ||
EV | 9,579,409 | 11,160,618 | 7,867,045 | ||
EBITDA | 4,103,120 | 4,085,866 | 2,909,453 | ||
EV/EBITDA | 2.33 | 2.73 | 2.70 | ||
Interest | 9,368 | 9,689 | 9,984 | ||
Interest/NOPBT | 0.29% | 0.31% | 0.50% | ||